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ABSTRACT 
 
 
Effects of Ractopamine HCl on Physical and Reproductive 
Parameters in the Horse. (May 2008) 
Russell Derek Kriewald, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Martha M. Vogelsang 
 
 The objective of this study was to monitor the effects on physical and 
reproductive parameters in mares supplemented with Ractopamine HCl (RAC), in an 
effort to provide some insight concerning the use of RAC in horse diets. Physical 
deviation was recorded via measurements of body weight (BW), muscle size, and fat 
deposition. Reproductive deviation was recorded via ultrasonographic measurement of 
follicular growth and ovulation, while hormonal analyses were conducted for leptin and 
luteinizing hormone (LH). Data analyses of physical measurements indicated an effect of 
RAC supplementation (P<.001) as treated horses had a greater increase in BW compared 
to the controls. Treatment horses increased gaskin circumference (P<.001) compared to 
horses on the control diet. Both groups showed an increase in rump fat with the treated 
horses gaining less (P<.05). A similar effect was revealed in body fat percentage (P<.01) 
with the treated horses gaining less when compared to the controls. No statistical 
differences were noted for changes in forearm circumference or rib fat. No change was 
derived for length of estrous or pre-ovulatory follicle size between groups. When 
analyzing the data from first to last cycle in the treatment group, length of estrous was 
significantly (P<.05) shortened over the 90-d study. Upon analysis of serum leptin 
concentrations, the control group had a significantly (P<.001) higher overall 
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concentration as compared to the treated horses; however, no difference was noted for 
normalized data, though RAC supplementation may have caused the profile of leptin to 
become more erratic. Analysis of LH concentrations revealed a strong trend (P=0.0527) 
of RAC-supplemented horses having a lower mean concentration of LH throughout the 
90-d study as compared to the controls. Means were also analyzed for day and treatment 
by day effects, suggesting possible trends (P=0.2944 and P=0.1591 respectively) of 
seasonality. Area Under the Curve (AUC) was calculated for individual horses and 
analyzed for treatment effects. Only a trend (P=0.1631) was noted for RAC-
supplemented horses having a smaller AUC (80.10 ± 29.72) as compared to the controls 
(140.60 ± 27.50). 
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CHAPTER I 
 
INTRODUCTION 
 Today’s horse industry is an extremely competitive market that is continuously 
evolving. Over time, breeders have manipulated and produced bloodlines that began with 
a strong foundation of quality breeding stock. To be productive, a breeder must choose 
individual animals for breeding based on quality, conformation, physical ability, and 
temperament. However, owners and trainers oftentimes fail to consider the effects on 
other parameters of physiology that a certain product or practice can cause. It is this train 
of thought that necessitates extensive research into any product which is used to enhance 
show ring preparations and performance of the horse. 
 A mare intended for breeding must be in optimal body condition to efficiently 
achieve and maintain a pregnancy to term. Nevertheless, for a show ring appearance, 
mares are expected to be more fit, representing the ideal standards for the particular class. 
At times, owners will go to any extent to gain a competitive edge in the show ring. One 
way of achieving this edge is by introducing the use of a supplemental product that gives 
the desired physical changes in the horse’s training program. While use of such products 
can give desirable outcomes in the near term, they may decrease the mare’s worth as 
breeding stock after her show ring career. 
 There are numerous products that claim to enhance the performance of the horse, 
thus giving the competitive edge a horseman might desire. These enhancements could 
include lean muscle growth resulting in muscle strength, delay of fatigue, overall growth,  
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or any other effect which could better prepare a horse for the intended task. One of the 
most recognized products used to obtain these effects is an anabolic steroid. Though these 
steroids can have a therapeutic use for debilitated horses, they also present the possibility 
to enhance a horse’s maximal athletic performance. After research identified adverse 
effects to both the mare’s and stallion’s reproductive physiology and behavior, steroid 
usage in competitive horses was banned throughout the industry. Now, horsemen seek the 
next available “miracle” product to obtain the same effects. Many times, species barriers 
are crossed, and uneducated decisions are made which jeopardizes the overall 
reproductive success in horses. 
 It has been suggested that Paylean®, a feed additive developed for swine, is 
currently being used to enhance performance in the horse industry. Ractopamine HCl 
(RAC) is a β-adrenergic agonist and growth regulator that is marketed under the product 
names Paylean® (for swine) and Optaflexx® (for cattle) (Elanco, Indianapolis, IN). Diets 
supplemented with RAC as an active ingredient have been shown to promote lean muscle 
gain and feed efficiency in swine via stimulation of lypolysis and protein synthesis, as 
well as the down regulation of lipogenesis (Kelly et al., 2003). Due to steroid-like effects 
and the depletion of adipocytes, there should be concern with respect to effects on 
reproductive physiology. 
 In swine, Paylean® is not recommended for use in breeding gilts. The dramatic 
decrease in adipose tissue could potentially have severe negative effects on the animal’s 
hormone profile and its ability to remain reproductively sound. Leptin, which is 
suggested to be the hormonal factor that signals the nutritional status to the reproductive 
system, is secreted in a circadian rhythm by adipocytes and is therefore likely to mediate 
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growth and reproductive performance. When adipocytes are depleted, there are fewer 
cells capable of secreting leptin. As a lack of leptin suppresses hypothalamus and 
pituitary function, gonadatrophic hormones such as luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) are likely to be inhibited, thus suppressing reproductive 
performance by interfering with normal ovarian function. 
 The results of this study could introduce key knowledge on how dietary 
supplementation of horses with Paylean® affects physical and reproductive parameters in 
the horse. Members of the horse industry may find this information applicable to the 
current off-label administration of Paylean® in horses, and as well, may find it pertinent 
to strictly regulate the use of the product. It is critical to uncover any possible routes in 
which a toxicity or disruption in physiology may occur in order to prevent such 
detriments to the industry. 
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CHAPTER II 
 
REVIEW OF LITERATURE 
β-agonists – An Overview 
 Nearly every mammalian cell type contains β-adrenergic receptors (β-AR) that 
are stimulated via norepinephrine and epinephrine. The physiological response of 
particular cells depends upon the composition of the β-AR subtypes present, and as well 
the species-specific amino acid sequence. Oral administration of some β-agonists can 
cause accretion of skeletal muscle and decreased fat deposition in swine, cattle, and other 
meat-animal species. Knowledge of those effects proposes direct actions on both skeletal 
muscle and adipose tissue. However, the overall effect of a given β-AR within a given 
species may also be controlled by other physiologic mechanisms including blood flow, 
hormone secretion, and by feed intake as controlled by the central nervous system 
(Mersmann, 1998). As animals mature and grow, not only do they receive differing diets, 
but cells change and proliferate, which may cause the animal to become more or less 
sensitive to such a product. Additionally, as species differ in feed consumption and 
hormonal profiles, the effects of such β-agonists would likely differ.  
 Increased skeletal muscle growth is the primary effect noted when a β-agonist is 
administered to a meat-animal species. It is speculated that the cause of increased muscle 
growth is due to an increase in protein synthesis, a decrease in protein degradation, or a 
combination of both (Yang and McElligott, 1989; Moloney et al., 1991). Though these 
mechanisms have been demonstrated in previous research, some reports have been unable 
to demonstrate such actions (Bergen et al., 1989; Claeys et al., 1989). 
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 Secondary to muscle growth is the depletion of adipose tissue, or a decrease in 
carcass fat mass due to stimulation of adipocyte degradation. The effects on adipose 
tissue, however, are not as consistent as the finding on skeletal muscle. Though a 
decrease in fat mass is reported when such an agonist is fed, some studies have indicated 
little or no effects on lipid metabolism in-vitro (Spurlock et al., 1993, 1994). 
 Due to the presence of β-AR on multiple cell types throughout the body, the 
effects of a β-agonist are likely to be more extensive, as well indirect, in the recipient 
animal. β-agonists, such as epinephrine, increase blood flow to various parts of the body. 
For instance, increasing blood flow to skeletal muscle tissue can certainly increase the 
amount of substrates and energy available for protein synthesis and muscle growth. 
Additionally, an increased blood flow through adipose tissue can assist in transporting 
nonesterified fatty acids away from the tissue, thus enhancing the rate of lipid 
degradation (Mersmann, 1998). Increased blood flow to the hindlimbs has been noted for 
both cattle (Eisemann et al., 1988) and sheep (Beermann et al., 1987), and both skeletal 
muscle and adipose tissue in swine (Mersmann, 1989). These effects are likely a result of 
the increase in heart rate noted for multiple β-agonists (Mersmann, 1987), and may 
further assist the more direct and commonly noted effects in meat-animal species. 
 
Ractopamine HCl (RAC) 
Ractopamine HCl (RAC) is a β-adrenoceptor agonist that exists in two 
diasteriomeric forms due to the presence of two chiral carbons. The racemic preparation 
has been approved as a feed additive for use in finishing swine and cattle. Ractopamine 
HCl is utilized as a growth promotant, and has a repartitioning effect by transferring 
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nutrients from fat deposition to protein synthesis and accelerated lean muscle gain. 
Developed by the Elanco Animal Health company, RAC was first approved by the FDA 
for use in finishing swine in 2000 to facilitate growth and feed efficiency. To stay 
competitive with other meat species, profit driven swine producers utilize RAC, in the 
commercial formulation of Paylean®, to provide health-conscious consumers with a 
leaner meat product. 
Previously, RAC has been found to be absorbed in the gastrointestinal tract when 
supplemented orally, and was detected by metabolites found in horse urine (Lehner et al., 
2004). The same study noted that, due to the metabolites recovered, RAC is metabolized 
in a similar way as in other species, such as swine, even though the rate of 
supplementation was considerably lower (less than 1mg/kg BW fed to horses compared 
to a range of 5-20mg/kg BW fed to pigs). Buff et al. (2006) hypothesized the potential 
efficacy of using RAC as a weight loss supplement in obese pony mares in a negative 
energy balance. Comparisons were made when ponies were fed RAC at 0 mg/kg, 0.6 
mg/kg, and 1.0 mg/kg BW. All pony mares, regardless of dietary group, decreased body 
weight over time. However, a greater decrease in BW was observed when RAC was fed 
at 1.0 mg/kg as compared to the control (0 RAC) and 0.6 mg/kg groups. This decrease in 
body weight could be further enhanced by the fact that all ponies were restricted to 75% 
of ad libitum intake. Thus, it was possible to use RAC in order to decrease BW in obese 
ponies. This finding is especially important due to the fact that obesity is commonly 
associated with other problems, such as laminitis, that inhibit the horse’s ability to 
exercise adequately. Some horses are genetically predisposed to obesity. In swine, 
research has proven RAC can be utilized to improve the efficiency of feed utilization 
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while promoting the leanness of a carcass regardless of the propensity of fat deposition 
(Yen et al., 1990). Swine supplemented with RAC had less fat depth, yet a higher 
dressing percentage was achieved. 
Prior studies in swine commonly note that consumption of RAC at differing levels 
resulted in increases in BW and percent yield and lean. Kelly et al. (2003) evaluated the 
response of feeding RAC on weight gain, feed intake, carcass value and economic return 
in finishing pigs. This study demonstrated an increase in body weight over the 4-wk 
feeding period, with 50% of the total weight gain occurring within the first week of 
treatment. Additionally, percent yield and lean also increased over the duration of the 
study. Though horses are not typically recognized as market animals nor evaluated for 
carcass characteristics, the goal of lean muscle growth remains the same, especially for 
show ring appearances. 
 
Toxicological Effects 
 As new products are introduced to alter an animal’s physiologic state, creating 
toxicity within that individual should be of concern. This is especially true when products 
are fed off-label, such as in a non-approved species, and the consumer lacks the 
appropriate information to make sound decisions. The use of RAC in horse diets is not 
approved, and is therefore illegal. Little evidence is available to judge the safety of RAC 
in horses. Research to date (Buff et al., 2006), including the present study, has fed 
relatively low levels of RAC compared to the typical dose administered to swine. The 
upper limits of RAC supplementation in horse diets is unknown, therefore the issue 
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should be approached cautiously. Though β-agonists have varying effects across species, 
information can be gathered from other species to make a hypothesis. 
 Unfortunately, most of the toxicological data obtained by Williams and associates 
has been conducted through the Toxicology Division of Lilly Research Laboratories 
(Elanco Animal Health, Indianapolis, IN), and is unpublished. Initially, short-term studies 
in toxicology were conducted on crossbred swine. Though swine tolerated the highest 
does of 15mg/kg BW per day without physical signs of toxicity, erythrocyte number and 
volume fraction, as well as hemoglobin concentrations were decreased. However, a no-
observed-effect level (NOEL) was not identified (Williams et al., 1987 as found in 
Ungemach, 2004). In a long-term study conducted on both male and female mice, it was 
found that the highest dose of RAC for both males (840 mg/kg BW per day) and females 
(1085mg/kg BW per day) exceeded the maximum tolerance level for mice (Williams, 
1998 as found in Ungemach, 2004). The study noted a 25% survival rate for males and a 
32% survival rate for females at the highest dose. Mortality rates at this dose were 
thought to be attributed to an increased severity of cardiomyopathy. For the male mice, 
the NOEL was determined to be 25mg/kg BW per day. However, a NOEL was not 
established for the female as a dose-dependant increase of uterine leiomyomas.  
 
A Comparison to Anabolic Steroids 
Anabolic steroid use in the equine industry has been of great interest for several 
decades due to its ability to alter or improve performance. Since then, steroid usage has 
been closely monitored and restricted by all equine organizations, though many horse 
owners still insist on finding a substitute for steroids without considering adverse effects. 
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The comparison between RAC and steroids is an important issue as both products can 
induce similar physical changes including an increase in BW and lean, delineated muscle 
gain. However, they might not cause the same changes from a reproductive aspect as 
RAC is instead, a growth promotant, not a hormone. A study conducted in 1980 analyzed 
the effects on reproductive function of two different steroids in yearling mares (Maher et 
al., 1983). Investigators noted that all mares receiving an anabolic steroid treatment failed 
to display normal estrous behavior; instead a more aggressive behavior toward other 
horses was noted. Additionally, the steroid treatment resulted in mares having fewer 
estrous cycles and ovulations, as well as a decrease in ovarian size and number of 
growing follicles. These occurrences can be further supported by the depression of LH, 
FSH, and progesterone that was observed. Disruption of the normal hormonal profile 
would essentially cause a negative effect on reproductive performance by suppressing the 
normal cyclicity of the mare. Though the investigators did not assess muscle mass, the 
anabolic steroid treatment did not have an effect on weight gain or height at the withers. 
The study concluded that due to the detrimental effects, anabolic steroids are not 
recommended for use in mares intended for reproductive use. Additional studies have 
noted that both mares and stallions exhibit altered sexual behavior due to anabolic steroid 
injections (Squires et al., 1982; 1983), however growth rates are not affected (Burke et 
al., 1981). Though RAC is not a hormone, the results of its administration, such as the 
depletion of adipocytes in extreme cases, could prove to have a negative effect on 
reproductive performance. 
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A Comparison to Clenbuterol (CBL) 
Clenbuterol HCl, a β-agonist of the same class as RAC, has been shown to have 
similar repartitioning effects in horses as RAC (Kearns et al., 2001); however due to the 
presence of a halogenated aromatic ring, it has a longer half life than does RAC with a 
hydroxylated aromatic ring (Smith, 1998). Though clenbuterol is primarily administered 
as a therapeutic agent to resolve bronchospasm and chronic obstructive pulmonary 
disease (COPD) in race horses, an accelerated rate of supplementation can result in 
repartitioning effects. Unfortunately, like many drugs, its abuse can lead to increased or 
abnormal heart rates and other cardiac irregularities. These adverse effects could cause a 
horse to be more susceptible to stress. Due to clenbuterol’s similarities as a β-agonist, the 
same concerns should be evaluated to determine the safety of RAC when administered in 
horse diets. Furthermore, data have revealed that RAC-supplemented pigs are potentially 
more susceptible to handling and transport stress due to hyperactivity, and higher heart 
rates during transport (Marchant-Forde et al., 2003). It has been well accepted by the 
swine community that special care should be taken when handling RAC-supplemented 
pigs to reduce the risk of “Downer Pigs.” 
 
A Reproductive Perspective 
Although RAC is not currently recommended for use in breeding animals, there is 
little evidence identifying potential effects on reproduction. An unpublished report 
(Williams, 1989 as found in Ungemach, 2004) concerning crossbred swine fed 
ractopamine suggested that the reproductive performance of gilts would not be negatively 
affected after supplementation ceased. Gilts were fed a diet containing either 20 or 
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60mg/kg BW of RAC. Following withdrawal, gilts were bred, allowed to farrow and 
nurse. There was no effect determined on reproductive performance. However, due to 
inappropriate standards of protocol, this study was not deemed suitable to assess the 
safety of ractopamine. Though RAC is not expected to be directly involved hormonally 
like a steroid, the dramatic increase in muscle gain and decrease in adipose tissue, as seen 
in swine, could potentially be adverse to normal reproductive physiology in the mare. 
In extreme cases, the depletion of adipocytes in the mare could cause an indirect 
route of interference with the normal reproductive cycle. In many farm animal species 
such as cattle and sheep, dietary energy restriction can lead to impaired reproductive 
function such as a delayed onset of puberty, as well as the induction and prolonging of 
anestrus (Rutter and Randel, 1894; Schillo 1992). This is achieved by certain effects on 
the pituitary’s function to release gonadatropins. Nutrition and reproductive efficiency 
has been correlated in the horse (Henneke et al., 1983, 1984; Hines et al., 1987). 
However, in the mare, the relationship between nutritional status and reproductive 
hormone release is not entirely understood. Nevertheless, mares in a moderately fat 
condition withhold adequate energy reserves (body fat) to meet the high-energy demands 
of reproduction. Additionally, mares entering the breeding season in thin condition have 
lower pregnancy rates and a higher number of cycles per conception (Henneke et al., 
1984).  In more recent years, research has further determined that the continuous 
reproductive activity exhibited by some mares is associated with a higher concentration 
of leptin, body weight, and an estimated percent body fat (Ferreira-Dias et al., 2002). 
First discovered in the mouse, leptin is an “adipostatic” hormone that regulates multiple 
metabolic processes including fertility (Henson et al., 2003). Leptin secretion can be 
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down-regulated by multiple factors including fasting, decreased adiposity, β-agonists, and 
growth hormone (Ahren et al., 1997; Considine and Caro, 1997; Houseknecht et al., 
2000). However, leptin concentrations in the horse can be greatly variable due to their 
large body mass. A species with a large body mass has a greater availability of oxidizable 
energy stores to counteract the negative response of the hypothalamic-pituitary-gonadal 
axis to feed reduction (McManus and Fitzgerald, 2000). As leptin has been deemed as the 
signal between body fat and the hypothalamus (Houseknecht et al., 1998), it is possible 
for gonadatropin secretion (LH and FSH) to be affected. For instance, dietary energy 
restriction in cattle and sheep suppresses the episodic release of LH (Schillo, 1992). As 
well, the absence of ovulation and the inability to form a functional corpus luteum has 
been correlated with low body condition in mares (Gentry et al., 2002). A study 
conducted by McManus and Fitzgerald (2000) demonstrated that circulating levels of 
leptin decreased in both young and aged mares when placed under a short term feed 
restriction; however, serum levels of LH and FSH were not affected during the same 
study.   
 
Current Regulations 
 The use of clenbuterol and RAC is banned by the United States Equestrian 
Federation which is the governing body of all equine performance activities (U.S. 
Equestrian Federation, 2007), as well as the Association of Racing Commissioners, 
International as a ‘Class 2 Drug”, having a high potential for affecting the performance of 
the horse (ARCI, 2006). Despite current regulations on the use of RAC as a performance 
enhancing drug in equine entities, speculation exists that many owners and trainers insist 
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on its off-label use in horses. Detection of RAC and its metabolites is achieved through 
performing an enzyme-linked immunosorbent assay (ELISA) of horse urine (Lehner et 
al., 2004) 
Thus far, only anecdotal evidence has suggested the efficacy of RAC 
supplementation to horse diets to induce weight loss. Published research does not provide 
an in depth investigation to changes in physical parameters in the horse, as compared to 
publications in both swine and cattle. Furthermore, little is known about the effects RAC 
could have on normal reproductive physiology within any species. 
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CHAPTER III 
 
MATERIALS AND METHODS 
 
 
Management of Horses 
 Thirteen fillies of varying ages (2, 3, and 5 years old), of stock horse type, were 
used in this study. All horses utilized were property of the Texas A&M University 
Department of Animal Science, and were maintained by the staff and facilities of the 
Texas A&M University Horse Center and N.W. “Dick” Freeman Arena. Maintenance 
and general care of all horses throughout this study conformed to the guidelines set forth 
by the Institutional Agricultural Animal Care and Use Committee (AUP# 2006-106). 
 Horses were housed in approximately 3.1m X 3.1m stalls, and received a 
moderate level of exercise 5 d per wk. Additional lighting was utilized to serve as an 
artificial photoperiod to ensure 16 hr per d of light exposure consistent with the seasonal 
reproductive period in the horse. All horses received a commercially available 
concentrate (Producer’s Cooperative Association, Bryan, TX) containing 13% crude 
protein at 1% BW per d. Feedings for each horse were adjusted weekly according to the 
recorded weekly BW. The remainder of the diet consisted of average quality coastal 
bermudagrass hay, and water was provided ad libitum. All feedings were conducted at 
0630 and 1730 daily throughout the 90-d period. 
 Horses observed in the treatment group received the same diet as explained 
previously, however, with the addition of RAC HCl at a rate of 0.6mg/kg BW per d, 
which was also adjusted according to weekly changes in BW. This oral supplement was 
top dressed to the morning feed for each horse in the treatment group. 
  
15
Experimental Procedure 
 The thirteen fillies were randomly divided into 2 dietary groups: the control group 
(n=7) and the treatment group (n=6). All horses began the experimental period on 
September 10, 2006 (d 0) and ended the experimental period on December 10, 2006 (d 
90). All horses remained in their respective dietary group and received the appropriate 
diet, according to individual BW, throughout the 90-d period.  
 
Physical Measurements  
 Body weights for each individual horse were recorded beginning on d 0, and then 
weekly for the remainder of the study. These measurements were recorded prior to 
feeding at the same time each day to minimize effects of digestive fill. Body weight 
measurements were further used to make weekly adjustments to diets for all horses, as 
well as the supplemental RAC HCl. 
 Forearm and gaskin circumference were measured weekly, beginning on d 0, at 
the widest point of each muscle group using a simple measuring tape. The left forearm 
and right gaskin muscles were observed to prevent any confounding effects of side-
specific exercise. Additionally, the area measured was also clipped to assure the same 
point was measured during each collection period. 
 Rump fat and rib fat measurements were collected weekly, beginning on d 0, via 
ultrasonic scanning equipment with a 5MHz transducer (Medison SonoVet 600®, 
Universal, Bedford Hills, NY). Rump fat measurements for all horses were taken from an 
area central to the length of the hip and 5.00 cm from the midline. Rib fat measurements 
were collected from an area over the ribs, precisely between the point of the withers and 
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point of the hip, and 45.00cm lateral from the midline. Body fat percentage was 
calculated from the appropriate rump fat values obtained throughout the study. 
 
Reproductive Measurements 
 Follicular growth and ovulation schedules were tracked via rectal palpation and 
ultrasound twice per wk, or every 3 to 4 d, beginning prior to d 0. The largest follicle on 
each ovary was measured and recorded via ultrasonic scanning equipment with a 5MHz 
transducer (Medison SonoVet 600®, Universal, Bedford Hills, NY). Additionally, the 
presence of a corpus luteum on the ovary was also recorded as an indicator of ovulation. 
 
Serum Sampling 
 Blood was collected from each horse using jugular venipuncture beginning on d 
0, and continuing on an every other day basis. Blood samples were collected at 0600 
before feeding to minimize fluctuations in circulating hormone concentrations. Upon 
collection, blood samples were transported on ice in preparation for centrifugation. All 
samples were centrifuged within 2 h of collection in a refrigerated centrifuge. Centrifuge 
temperature was 5°C and samples were spun at 2500rpm for 30 min. Upon completion of 
centrifugation, serum was separated and stored in micro-centrifuge tubes at -20°C for 
subsequent hormone analysis. 
 
Radioimmunoassay (RIA) Procedures 
 Serum concentrations of leptin and luteinizing hormone (LH) were analyzed via 
RIA for horse samples. All samples from each horse were analyzed in a single assay for 
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each hormone. All unknown assay samples were run in duplicate while standards and 
reagents were run in triplicate.  
 Serum leptin concentrations were measured on a weekly basis using a multi-
species leptin RIA kit (Linco Research, Inc., St. Charles, MO.). A serum sample volume 
of 100µl was used with a sensitivity of 1.0 ng/ml. Leptin assays were analyzed using a 
Packard Cobra II® gamma counter. Location of assay was conducted at Texas A&M 
University – Kleberg Center, College Station, Texas. 
Serum LH concentrations were measured on an every other day basis using e-LH 
RIA procedures (Williams et al., 2007). A serum sample volume of 200µl was used with 
a sensitivity of 0.10ng/ml. Luteinizing hormone assays were analyzed using a Perkin 
Elmer gamma counter. Assays were conducted in conjunction with Dr. Gary L. Williams 
and staff at the Animal Reproduction Laboratory, Texas Agrilife Research Station, 
Beeville, Texas. 
 
Statistical Analyses 
 Statistical analysis was conducted on all physical parameters, including leptin, by 
analysis of variance (ANOVA) using STATA statistical software (Stata Corp., College 
Station, TX). Physical parameters were analyzed as the mean change from d 0 to 
establish a baseline. Raw data was initially analyzed for leptin; however, due to numeric 
variability between horses and groups at d 0, normalized values are also represented.  
 Data collected for length of estrous cycle, pre-ovulatory follicle size, and 
luteinizing hormone (LH) concentrations were analyzed using the mixed linear model 
(PROC MIXED) of SAS (2007). Least squares means and standard errors were obtained 
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according to treatment, cycle and treatment by cycle for length of estrous cycle and pre-
ovulatory follicle size; where as treatment, day and treatment by day was utilized for LH. 
Main treatment effects were analyzed using horse within treatment as the error term. 
 Statistical significance was declared at probabilities <0.05 for all data, with 
probability values between 0.05 and 0.20 being considered to be trends towards 
significance. 
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CHAPTER IV 
 
RESULTS 
Physical Measurements 
 Body weight was measured on a weekly schedule not only to provide accurate 
RAC supplementation, but also to monitor the weekly response to RAC and to determine 
the overall change in body weight during the supplemental period. Statistical analysis of 
the data (Table 1) indicated an effect of RAC supplementation as treated horses had a 
greater increase in BW (P<.001) compared to the controls. Since both groups began at 
differing body weights, only the changes in means from d 0 to d 90 are represented in 
order to establish a baseline reference.  
 
Table 1. Mean (± SE) body weight measured in mares fed a control or RAC-
supplemented diet. 
                                         Body Weight 
   (kg)  
    Initial Final Change 
Control  444.29 ± 8.7 461.95 ± 7.3 17.66a ± 3.8 
     
Treatment   423.33 ± 20.3 448.18 ± 17.0 24.85b ± 6.5 
a,b Means within columns with different superscripts differ (P<.001) 
 
 
Muscle growth was monitored for both groups by measuring the circumference 
around the widest point of both the forearm and gaskin muscles. The point of 
measurement was shaved to ensure exact location of subsequent recordings, and 
measurement was performed by the same individual to decrease the likelihood of error in 
measuring. Though  no change was observed in forearm circumference (Table 2) for 
either group, data indicated that treatment horses increased gaskin circumference by a 
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mean of 0.67 ± 0.2 cm (P<.001) compared to 0.00 ± 0.0 cm for the horses on the control 
diet (Table 3). 
 
Table 2. Mean (± SE) forearm circumference measured in mares fed a control or RAC-
supplemented diet. 
    Forearm Circumference 
   (cm)  
    Initial Final Change 
Control  53.33 ± 0.5 53.51 ± 0.6 0.19 ± 0.2 
     
Treatment   52.12 ± 1.0 52.58 ± 1.2 0.47 ± 0.5 
 
 
 
Table 3. Mean (± SE) gaskin circumference measured in mares fed a control or RAC-
supplemented diet. 
                             Gaskin Circumference 
   (cm)  
    Initial Final Change 
Control  45.97 ± 0.6 45.97 ± 0.5 0.00a ± 0.0 
     
Treatment   44.53 ± 0.9 45.20 ± 0.9 0.67b ± 0.2 
a,b Means within columns with different superscripts differ (P<.001) 
 
 
Although there was no difference in the change in rib fat (Table 4), both groups 
showed an increase in rump fat (Table 5) with the treated horses gaining less rump fat 
(P<.05). A similar effect was revealed in body fat percentage (P<.01) with the treated 
horses gaining less when compared to the controls (Table 6). This can be expected as 
rump fat values were utilized in calculation of percent body fat values according to the 
equation: Y= 8.64 + 4.70 X (Westervelt et al., 1976). As both groups indicated similar 
loss of rib fat, this parameter could be attributed to the exercise requirements under 
saddle.   
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Table 4. Mean (± SE) rib fat measured in mares fed a control or RAC-supplemented 
diet. 
                                         Rib Fat 
   (mm)  
    Initial Final Change 
Control  4.14 ± 0.6 3.14 ± 0.1 -1.00 ± 0.6 
     
Treatment   3.83 ± 0.3 2.83 ± 0.2 -1.00 ± 0.4 
 
 
 
Table 5. Mean (± SE) rump fat measured in mares fed a control or RAC-
supplemented diet. 
                                       Rump Fat 
   (mm)  
    Initial Final Change 
Control  5.43 ± 0.9 9.29 ± 1.1 3.86a ± 0.7 
     
Treatment   4.83 ± 0.4 7.33 ± 0.8 2.50b ± 0.6 
a,b Means within columns with different superscripts differ (P<.05) 
 
 
 
Table 6. Mean (± SE) percent body fat measured in mares fed a control or RAC-
supplemented diet. 
                                        Body Fat 
      (%)   
  Initial Final Change 
Control  11.20 ± 0.4 12.99 ± 0.5 0.93a ± 0.1 
     
Treatment   10.92 ± 0.2 12.07 ± 0.4 0.73b ± 0.1 
a,b Means within columns with different superscripts differ (P<.01) 
 
 
 
 
Reproductive Measurements 
 Mean estrous cycle length was counted in days from one ovulation to the next 
throughout the duration of the study.  Ovulation was monitored twice per week beginning 
at the first recorded corpus luteum (CL) to the presence of a subsequent CL. Mean pre-
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ovulatory follicle size was measured and was the mean (mm) of the largest follicle 
measured before ovulation for each group. Initial values were taken beginning on d 0 and 
final values ended at d 90. Upon analysis of length of estrous cycle, there were no 
treatment or treatment by cycle effects; however, treatment horses did experience a 
shorter estrous cycle at the conclusion of the study as compared to initial cycle length 
within that group (Table 7). On average, there was no difference associated with mean 
length of cycle between groups throughout the study. There were no observed effects for 
pre-ovulatory follicle size, although numerically, treatment horses on average sustained a 
larger pre-ovulatory follicle size for the entire study (Table 8). 
 
    
Table 7. Mean (± SE) length of estrous cycle in mares fed a control or RAC 
supplemented diet. 
  Length of Estrous Cycle 
 (d) 
  First Cycle Last Cycle Mean Cycle Length 
Control 24.29 ± 5.9 21.70 ± 1.9 23.11 ± 1.6 
    
Treatment 33.43 ± 5.9a 15.16 ± 2.1b 23.15 ± 1.7 
a,b Means within rows with different superscripts differ (P<.05)  
 
 
Table 8. Mean (± SE) pre-ovulatory follicle size in mares fed a control or RAC 
supplemented diet. 
  Pre-Ovulatory Follicle Size 
 (mm) 
  First Cycle Last Cycle Mean Size 
Control 35.57 ± 1.7 38.67 ± 2.3 35.99 ± 1.1 
    
Treatment 37.00 ± 1.7 34.00 ± 2.8 36.34 ± 1.2 
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Hormone Analyses: Serum Leptin 
 Serum Leptin concentrations were measured on a weekly schedule beginning on d 
0 to further support the results concluded from body fat measurements and to determine if 
RAC supplementation had an effect on circulating hormone concentrations.  Though 
blood samples were taken every other day, a weekly sample (same day for all horses) was 
utilized to determine the weekly fluctuation of the leptin concentration profile. Statistical 
analysis of raw data indicated an effect (P<.001) of RAC on circulating levels of leptin 
with the treatment group having a lower total concentration at the end of the 90-d period 
(Table 9).  
 
Table 9. Mean (± SE) serum leptin concentrations (ng/ml) in mares fed a control or 
RAC-supplemented diet. 
Week   Control  Treatment 
0  2.7 ± 0.7  1.6 ± 0.2 
1  3.2 ± 0.8  1.9 ± 0.4 
2  2.8 ± 0.7  1.9 ± 0.3 
3  2.7 ± 0.7  1.7 ± 0.3 
4  2.8 ± 0.7  2.0 ± 0.4 
5  2.9 ± 0.8  1.9 ± 0.3 
6  3.0 ± 0.8  2.1 ± 0.3 
7  3.0 ± 0.8  1.8 ± 0.4 
8  3.0 ± 0.8  2.0 ± 0.4 
9  3.1 ± 0.9  2.1 ± 0.4 
10  3.0 ± 0.9  2.0 ± 0.4 
11  3.0 ± 0.9  2.2 ± 0.5 
12  3.2 ± 0.9  2.3 ± 0.4 
13  2.9 ± 0.9  2.1 ± 0.4 
Overall Total   2.9a ± 0.2  2.0b ± 0.1 
a,b Means between columns with different superscripts differ (P<.001). 
 
 
 
However, this lower concentration was already present at the beginning of the 
study, but not significantly different between groups. Due to this slight variability 
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between groups at d 0, normalized values are represented to more accurately define the 
change in parameter (Figure 1). There were no significant differences in circulating leptin 
concentrations observed between groups using normalized values (Figure 1.) 
Nevertheless, this figure does represent the variability of circulating leptin concentrations 
noted in horses, and could possibly depict a trend that RAC may cause the leptin profile 
to become more erratic. 
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Figure 1. Normalized analysis of change in serum leptin concentrations measured 
in mares fed a control or RAC-supplemented diet. 
 
 
 
  
25
Hormone Analyses: Serum Luteinizing Hormone (LH) 
 Serum Luteinizing Hormone (LH) concentrations were measured every other day 
beginning on d 0 and ending on d 90 to verify ovulation and determine changes during 
the season and the supplemental period. Analysis of means between each group for each 
day were plotted (Figure 2.), and a strong trend (P=0.0527) was noted for RAC-
supplemented horses having a lower mean concentration of LH (0.88 ± .22) throughout 
the 90-d study as compared to the controls (1.53 ± .20).  
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Figure 2. Mean luteinizing hormone (ng/ml) concentrations measured in mares 
fed a control or RAC-supplemented diet. 
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Means were also analyzed for day (P=0.2944) and treatment by day (P=0.1591) 
effects, suggesting a possible seasonal effect throughout the study.  Due to the season in 
which the study was conducted (September-December), season could be a confounding 
variable. All horses were placed under an artificial photoperiod to assist in minimizing 
this effect, however not all horses responded similarly to the lighting regimen. In any 
case, the control horses appeared to numerically maintain a higher concentration of LH, 
depicted as the spike around d 52, while the RAC-supplemented horses remained 
suppressed (Figure 2) after the initial LH peak. 
Area Under the Curve (AUC) was calculated for individual horses and analyzed 
for treatment effects by analysis of variance. Only a trend (P=0.1631) was noted for 
RAC-supplemented horses having a smaller AUC (80.10 ± 29.72) as compared to the 
controls (140.60 ± 27.50).  
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CHAPTER V 
 
DISCUSSION 
Previously, only anecdotal evidence has suggested the possible efficacy of RAC  
 
usage in horse diets. Published research does not provide an in depth investigation in to  
 
changes in physical parameters in the horse, as compared to publications in both swine  
 
and cattle. Although RAC is not recommended for use in breeding animals, there have  
 
been no reports identifying potential effects on reproduction. However, the dramatic  
 
increase in muscle gain and decrease in adipose tissue, as seen in swine, could potentially  
 
be adverse to normal reproductive physiology. 
  
The results of this study show similar trends to data obtained from swine fed RAC  
 
in the form of Paylean®. Prior studies in swine commonly note that consumption of RAC  
 
at differing levels resulted in increases in BW and percent yield and lean, which appears  
 
to agree with this study (Kelly et al., 2003; See et al., 2004). The current study  
 
contradicts the decrease in BW as seen in obese pony mares fed RAC. However, those  
 
ponies were restricted to 75% of ad libitum intake, whereas the current study did not feed 
 
for the same negative energy balance that would initiate weight loss.  
 
Leptin concentrations for obese pony mares (Buff et al., 2006) changed  
 
significantly over time; however there was no difference observed between groups. The  
 
current study indicates a change in mean overall serum leptin concentrations. Although,  
 
there was slight variability at the beginning of the study, and normalized data did not  
 
indicate any change between groups. Even so, it appears that RAC supplementation may  
 
have caused leptin to become more erratic over time. Additionally, data collected for LH  
 
concentrations indicated a strong trend for RAC-supplemented horses to have a lower  
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mean concentration throughout the 90-d period. As well, there were trends for day and  
 
treatment by day effects, suggesting a possible seasonal effect. Horses were placed  
 
under an artificial photoperiod, though not all horses responded as expected. In any case,  
 
it would appear that RAC may have caused a suppression of LH for the treatment horses  
 
as the control group numerically maintained higher levels of LH throughout the study.  
  
Administration of RAC in horse diets resulted in significant increases in BW and  
 
gaskin circumference, without affecting follicular growth and ovulation. However,  
 
restrictions are being placed on the use of RAC as a possible performance enhancing drug  
 
by the Association of Racing Commissioners, International among others (ARCI, 2006;  
 
U.S. Equestrian Federation, 2007).  Clenbuterol HCl, another β-agonist that is used in 
 
 horses as a therapeutic drug for bronchospasm and chronic obstructive pulmonary  
 
disease (COPD), has also been shown to have legitimate repartitioningeffects similar to 
 
RAC (Kearns et al., 2001). Although this drug has therapeutic intentions, the abuse of  
 
clenbuterol can lead to increased or abnormal heart rates and other cardiac irregularities, 
 
thus horses are more susceptible to stressors. Additionally, RAC supplemented pigs must  
 
be handled by less stressful methods for the same reasons.  
 
Coupled with the increased protein synthesis in muscle tissue, lysine deficiencies  
 
should also be of concern. Eli Lilly and Company (Elanco), which markets Paylean®  
 
and Optaflexx®, recommends feeding at least a 16% CP ration to pigs in order to prevent  
 
a lysine deficiency and support the accelerated protein synthesis to optimize the 
  
performance of RAC fed swine. However, lysine requirements and the lysine:energy  
 
value are thought to be greater in RAC-supplemented pigs and may be higher than what  
 
is currently being used in the industry (Apple et al., 2004). It appears that a diet  
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consisting of at least 1.0% dietary lysine will be suitable to optimize growth rate and lean  
 
yield in swine (Webster et al., 2002). 
 
As the industry becomes more competitive and more is expected from younger 
 
horses, meeting their nutritional requirements becomes a challenge. If such a product is  
 
used in younger, halter horses for example, an average diet could be lacking sufficient  
 
levels of lysine to support growth and development. Thus, further research should be  
 
conducted to reveal the safety of RAC supplemented diets in horses, and to evaluate any  
 
deficiencies or toxicities that may arise. 
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CHAPTER VI 
 
SUMMARY 
The present study monitored the effects of a RAC-supplemented diet on both 
physical and reproductive parameters in growing mares. Treatment horses were fed both 
the diet and supplement according to body weight in order to minimize non-RAC sources 
of variation. Physical measurements (BW, forearm circumference, and gaskin 
circumference) were recorded to monitor overall growth and muscle accretion. 
Additionally, fat thickness was measured (rib fat, rump fat, and percent body fat) to 
gauge the repartitioning effects of lean muscle growth. To help satisfy the concerns on 
reproduction, fillies were palpated to track follicular growth, ovulation, and corpus 
luteum maintenance. To further support the above information, serum samples were 
taken to monitor weekly changes in circulating leptin, and daily changes in circulating 
LH. Data collected was then analyzed to ensure accurate understanding of the parameters 
of concern. 
The results of this study indicate a lean muscle gain and decrease in body fat 
percentage in horses fed RAC, a response similar to that seen in swine and cattle. Body 
weight increased as a result of muscle gain and overall growth versus fat deposition. 
However, if RAC is to be used in horse diets, safe levels of supplementation to avoid 
possible protein deficiencies and cardiovascular abnormalities should be considered.  
In conclusion, the results obtained and presented in this study have provided the 
industry a closer look into the effects of RAC in horse diets as a repartitioning agent. 
Ractopamine does, in fact, initiate lean muscle growth even in smaller doses as compared 
to the typical doses supplemented to swine. Though no effects were noted for length of 
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estrous cycle or pre-ovulatory follicle size, RAC supplementation did appear to have an 
effect on mean serum leptin concentrations (no effect for normalized data), and multiple 
trends were noted for LH concentrations for horses supplemented with RAC. The results 
presented for hormone analyses are somewhat unclear due to possible seasonal effects. 
As this supplemental period was short-term, and again RAC was supplemented at 
relatively low levels, the effects of long-term and accelerated dosage levels on 
reproduction should still be questioned. Nevertheless, the analysis and results presented 
within this study illustrate RAC’s capability of altering growth and possibly performance 
in horses to the governing bodies of the equine industry. 
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Appendix Table 1A. Description of research horses. 
      
Horse Age Sex Breed Treatment  
      
Dee 2 Filly Quarter Horse RAC  
Missy 5 Filly Quarter Horse RAC  
Mark Kay 3 Filly Quarter Horse RAC  
Blue 5 Filly Quarter Horse RAC  
Scoot 2 Filly Quarter Horse RAC  
Prissy 2 Filly Quarter Horse RAC  
      
Total (RAC)    n=6  
      
Sun 2 Filly Quarter Horse Control  
Nina 3 Filly Quarter Horse Control  
Marla 3 Filly Quarter Horse Control  
Faces 2 Filly Quarter Horse Control  
Loreal 2 Filly Quarter Horse Control  
Slimer 2 Filly Quarter Horse Control  
Lena 3 Filly Quarter Horse Control  
      
Total (Control)       n=7  
 
 
 
 
 
Appendix Table 2A. ANOVA table for change in body weight (BW). 
      
Source DF Partial SS Mean Square F Value Pr>F
     
Model 27 13819.2851 511.825374 5.86 0.0000
Group 1 1386.55166 1386.55166 15.88 0.0001
Week 13 11617.915 893.685769 10.23 0.0000
Group*Week 13 1238.53908 95.2722373 1.09 0.3707
Residual 154 13448.0086 87.3247314  
     
Total 181 27267.2937 150.648032    
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Appendix Table 3A. ANOVA table for change in forearm circumference. 
      
Source DF Partial SS Mean Square F Value Pr>F
      
Model 27 5.17111709 0.191522855 0.27 0.9999
Group 1 0.10477369 0.10477369 0.15 0.7020
Week 13 4.00194787 0.307842144 0.43 0.9561
Group*Week 13 1.31029949 0.100792268 0.14 0.9998
Residual 154 109.792619 0.712939083   
      
Total 181 114.963736 0.635158762     
 
 
 
Appendix Table 4A. ANOVA table for change in gaskin circumference. 
      
Source DF Partial SS Mean Square F Value Pr>F
      
Model 27 10.4113736 0.385606429 3.73 0.0000
Group 1 6.0584825 6.0584825 58.61 0.0000
Week 13 3.18734165 0.245180127 2.37 0.0064
Group*Week 13 1.38909992 0.10685384 1.03 0.4221
Residual 154 15.9185715 0.103367348   
      
Total 181 26.3299451 0.14546931     
 
 
Appendix Table 5A. ANOVA table for change in rib fat thickness. 
      
Source DF Partial SS Mean Square F Value Pr>F
      
Model 27 44.1611722 1.63559897 1.17 0.2700
Group 1 2.0115123 2.0115123 1.44 0.2319
Week 13 33.8859236 2.60660951 1.87 0.0380
Group*Week 13 9.09471481 0.699593447 0.50 0.9214
Residual 154 215.047619 1.39641311   
      
Total 181 259.208791 1.43209277     
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Appendix Table 6A. ANOVA table for change in rump fat thickness. 
      
Source DF Partial SS Mean Square F Value Pr>F
      
Model 27 282.576923 10.465812 4.64 0.0000
Group 1 14.1602564 14.1602564 6.28 0.0132
Week 13 247.999084 19.0768526 8.46 0.0000
Group*Week 13 13.9990842 1.07685263 0.48 0.9344
Residual 154 347.071429 2.25371058   
      
Total 181 629.648352 3.47872017     
 
 
 
Appendix Table 7A. ANOVA table for change in body fat percentage. 
      
Source DF Partial SS Mean Square F Value Pr>F
      
Model 27 3.2873076 0.121752133 1.68 0.0272
Group 1 0.603141005 0.603141005 8.31 0.0045
Week 13 2.47999075 0.19076852 2.63 0.0024
Group*Week 13 0.13999086 0.010768528 0.15 0.9998
Residual 154 11.1707139 0.072537103   
      
Total 181 14.4580215 0.079878572     
 
 
Appendix Table 8A. ANOVA table for length of estrous cycle. 
            
Source DF Partial SSa Mean Squarea F Value Pr>F
     
Group 1   0.00 0.9873
Cycle 3   3.97 0.0198
Group*Cycle 3   1.46 0.2504
aColumns with superscript: values not calculated under Mixed Procedure for SAS. 
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Appendix Table 9A. ANOVA table for pre-ovulatory follicle size. 
            
Source DF Partial SSa Mean Squarea F Value Pr>F
      
Group 1   0.04 0.8413
Cycle 3   0.18 0.9063
Group*Cycle 3   0.99 0.4146
aColumns with superscript: values not calculated under Mixed Procedure for SAS. 
 
 
Appendix Table 10A. ANOVA table for change in serum leptin concentrations. 
      
Source DF Partail SS Mean Square F Value Pr>F
      
Model 27 47.8002209 1.77037855 0.60 0.9379
Group 1 42.6622459 42.6622459 14.54 0.0002
Week 13 4.19241046 0.322493112 0.11 1.0000
Group*Week 13 0.939813812 0.07229337 0.02 1.0000
Residual 154 451.818414 2.9338858   
      
Total 181 499.618635 2.76032395     
 
 
 
Appendix Table 11A. ANOVA table for normalized change in serum leptin 
concentrations. 
      
Source DF Partial SS Mean Square F Value Pr>F
      
Model 27 5.37812341 0.199189756 0.44 0.9934
Group 1 0.240148356 0.240148356 0.52 0.4700
Week 13 4.19241044 0.322493111 0.70 0.7569
Group*Week 13 0.939813882 0.072293376 0.16 0.9997
Residual 154 70.4943297 0.457755387   
      
Total 181 75.8724531 0.419184824     
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Appendix Table 12A. ANOVA table for mean serum LH concentrations.  
      
Source DF Sum of Squaresa Mean Squarea F Value Pr>F
      
Group 1   4.71 0.0527
Week 45   1.11 0.2944
Group*Week 45   1.22 0.1591
            
aColumns with superscript: values not calculated under Mixed Procedure for SAS. 
 
 
 
 
Appendix Table 13A. ANOVA table for serum LH concentrations (AUC).  
      
Source DF Sum of Squares Mean Square F Value Pr>F
      
Model 1 11825.42308 11825.42308 2.23 0.1631
Error 11 58226.4400 5293.31237   
      
Corrected Total 12 70051.863.08       
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Appendix Table 14A. Physical data collected on project horses. 
Horse Group Week BW  Forearm Gaskin Rib Fat  Rump Fat Rump Fat Body Fat 
   (kg) (cm)  (cm) (mm)  (mm)  (cm) (%)  
Dee RAC 0 434.09 51.0 44.5 4 4 0.4 10.5 
Dee RAC 1 436.36 51.0 44.0 4 4 0.4 10.5 
Dee RAC 2 433.18 51.2 44.1 4 5 0.5 11.0 
Dee RAC 3 444.09 51.2 44.1 4 4 0.4 10.5 
Dee RAC 4 448.18 51.2 44.1 3 4 0.4 10.5 
Dee RAC 5 449.55 51.2 44.1 3 4 0.4 10.5 
Dee RAC 6 450.91 51.2 44.1 3 5 0.5 11.0 
Dee RAC 7 458.64 51.3 44.1 2 6 0.6 11.5 
Dee RAC 8 460.00 51.5 44.1 2 7 0.7 11.9 
Dee RAC 9 462.27 51.7 44.3 2 7 0.7 11.9 
Dee RAC 10 466.82 51.9 44.3 2 7 0.7 11.9 
Dee RAC 11 480.45 52.0 44.5 3 8 0.8 12.4 
Dee RAC 12 470.91 52.0 44.5 3 7 0.7 11.9 
Dee RAC 13 469.55 52.0 44.6 2 7 0.7 11.9 
          
Missy RAC 0 436.36 53.4 44.8 3 5 0.5 11.0 
Missy RAC 1 454.55 53.4 44.9 2 5 0.5 11.0 
Missy RAC 2 432.73 53.6 45.3 2 5 0.5 11.0 
Missy RAC 3 453.64 53.7 45.4 2 5 0.5 11.0 
Missy RAC 4 457.27 53.9 45.6 2 5 0.5 11.0 
Missy RAC 5 455.45 53.9 45.6 2 6 0.6 11.5 
Missy RAC 6 460.00 54.1 45.6 2 6 0.6 11.5 
Missy RAC 7 456.82 54.2 45.7 2 6 0.6 11.5 
Missy RAC 8 460.45 54.2 45.7 2 7 0.7 11.9 
Missy RAC 9 461.36 54.2 45.7 3 7 0.7 11.9 
Missy RAC 10 460.00 54.3 45.7 3 7 0.7 11.9 
Missy RAC 11 476.36 54.4 45.8 2 9 0.9 12.9 
Missy RAC 12 465.91 54.4 45.9 3 7 0.7 11.9 
Missy RAC 13 471.36 54.6 46.1 3 7 0.7 11.9 
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Appendix Table 14A (Continued). Physical data collected on project horses. 
Horse Group Week BW  Forearm Gaskin Rib Fat  Rump Fat Rump Fat Body Fat 
   (kg) (cm)  (cm) (mm)  (mm)  (cm) (%)  
Mary Kay RAC 0 479.09 55.1 48.4 4 6 0.4 10.5 
Mary Kay RAC 1 484.09 55.1 48.4 4 9 0.4 10.5 
Mary Kay RAC 2 479.55 55.2 48.4 5 11 0.5 11.0 
Mary Kay RAC 3 490.00 55.2 48.4 4 9 0.4 10.5 
Mary Kay RAC 4 463.64 55.4 48.4 3 8 0.3 10.1 
Mary Kay RAC 5 487.27 55.4 48.4 2 8 0.2 9.6 
Mary Kay RAC 6 486.82 55.6 48.4 3 7 0.3 10.1 
Mary Kay RAC 7 495.45 55.7 48.5 2 8 0.2 9.6 
Mary Kay RAC 8 501.36 55.9 48.5 3 10 0.3 10.1 
Mary Kay RAC 9 507.73 56.0 48.5 3 11 0.3 10.1 
Mary Kay RAC 10 495.45 56.0 48.5 3 10 0.3 10.1 
Mary Kay RAC 11 507.25 56.1 48.7 3 12 0.3 10.1 
Mary Kay RAC 12 499.55 56.1 48.7 3 9 0.3 10.1 
Mary Kay RAC 13 492.73 56.1 48.7 3 10 0.3 10.1 
          
Blue RAC 0 464.55 54.0 44.7 4 4 0.4 10.5 
Blue RAC 1 458.09 54.0 44.9 3 4 0.3 10.1 
Blue RAC 2 447.73 52.0 44.9 4 6 0.4 10.5 
Blue RAC 3 455.45 52.2 45.1 4 6 0.4 10.5 
Blue RAC 4 477.27 52.2 45.1 2 4 0.2 9.6 
Blue RAC 5 456.36 52.2 45.1 3 4 0.3 10.1 
Blue RAC 6 453.18 52.3 45.0 2 4 0.2 9.6 
Blue RAC 7 455.00 52.3 45.1 2 4 0.2 9.6 
Blue RAC 8 460.00 52.3 45.2 2 5 0.2 9.6 
Blue RAC 9 460.91 52.3 45.2 2 5 0.2 9.6 
Blue RAC 10 454.54 52.3 45.3 3 5 0.3 10.1 
Blue RAC 11 476.82 52.3 45.3 3 5 0.3 10.1 
Blue RAC 12 479.55 52.4 45.3 3 4 0.3 10.1 
Blue RAC 13 462.27 52.5 45.4 3 4 0.3 10.1 
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Appendix Table 14A (Continued). Physical data collected on project horses. 
Horse Group Week BW  Forearm Gaskin Rib Fat  Rump Fat Rump Fat Body Fat 
   (kg) (cm)  (cm) (mm)  (mm)  (cm) (%)  
Scoot RAC 0 359.55 48.5 41.5 3 4 0.4 10.5 
Scoot RAC 1 364.09 47.6 41.7 4 4 0.4 10.5 
Scoot RAC 2 366.82 47.6 41.8 3 4 0.4 10.5 
Scoot RAC 3 375.00 47.5 41.8 3 3 0.3 10.1 
Scoot RAC 4 375.45 47.5 41.8 2 4 0.4 10.5 
Scoot RAC 5 374.55 47.5 41.8 2 5 0.5 11.0 
Scoot RAC 6 372.73 47.5 41.9 2 5 0.5 11.0 
Scoot RAC 7 380.45 47.5 42.0 2 5 0.5 11.0 
Scoot RAC 8 383.18 47.5 42.2 2 5 0.5 11.0 
Scoot RAC 9 386.36 47.5 42.2 2 5 0.5 11.0 
Scoot RAC 10 385.91 47.5 42.2 2 6 0.6 11.5 
Scoot RAC 11 394.55 47.5 42.2 2 8 0.8 12.4 
Scoot RAC 12 390.00 47.6 42.3 2 8 0.8 12.4 
Scoot RAC 13 388.64 47.7 42.4 3 7 0.7 11.9 
          
Prissy RAC 0 366.36 50.7 43.3 5 6 0.6 11.5 
Prissy RAC 1 366.36 51.4 43.3 3 5 0.5 11.0 
Prissy RAC 2 369.55 51.4 43.2 4 7 0.7 11.9 
Prissy RAC 3 379.55 51.4 43.2 4 7 0.7 11.9 
Prissy RAC 4 384.09 51.4 43.2 4 8 0.8 12.4 
Prissy RAC 5 380.91 51.5 43.4 2 8 0.8 12.4 
Prissy RAC 6 384.55 51.7 43.6 2 9 0.9 12.9 
Prissy RAC 7 390.91 52.0 43.7 2 9 0.9 12.9 
Prissy RAC 8 396.36 52.0 43.7 2 9 0.9 12.9 
Prissy RAC 9 400.00 52.0 43.8 2 9 0.9 12.9 
Prissy RAC 10 403.18 52.0 43.9 2 9 0.9 12.9 
Prissy RAC 11 413.64 52.0 44.0 3 11 1.1 13.8 
Prissy RAC 12 402.27 52.4 44.0 3 8 0.8 12.4 
Prissy RAC 13 404.55 52.6 44.0 3 9 0.9 12.9 
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Appendix Table 14A (Continued). Physical data collected on project horses. 
Horse Group Week BW  Forearm Gaskin Rib Fat  Rump Fat Rump Fat Body Fat 
   (kg) (cm)  (cm) (mm)  (mm)  (cm) (%)  
Sun Control 0 440.91 52.0 45.5 1 7 0.7 11.9 
Sun Control 1 441.36 52.9 45.5 3 7 0.7 11.9 
Sun Control 2 430.45 52.9 45.5 3 6 0.6 11.5 
Sun Control 3 444.09 52.9 45.7 2 6 0.6 11.5 
Sun Control 4 446.82 52.9 45.7 2 6 0.6 11.5 
Sun Control 5 445.00 52.9 45.7 3 7 0.7 11.9 
Sun Control 6 445.00 52.5 45.7 2 7 0.7 11.9 
Sun Control 7 440.91 52.5 45.7 2 7 0.7 11.9 
Sun Control 8 453.18 52.5 45.7 2 8 0.8 12.4 
Sun Control 9 452.27 52.5 45.7 2 7 0.7 11.9 
Sun Control 10 452.27 52.5 45.5 2 7 0.7 11.9 
Sun Control 11 452.27 52.5 45.5 3 9 0.9 12.9 
Sun Control 12 454.09 52.5 45.5 3 9 0.9 12.9 
Sun Control 13 453.18 52.5 45.5 3 9 0.9 12.9 
          
Nina Control 0 463.18 53.6 45.1 4 10 1 13.3 
Nina Control 1 467.27 53.6 45.1 4 12 1.2 14.3 
Nina Control 2 466.36 54.0 45.1 4 13 1.3 14.8 
Nina Control 3 475.45 54.3 45.2 4 13 1.3 14.8 
Nina Control 4 466.82 54.3 45.3 4 13 1.3 14.8 
Nina Control 5 478.18 54.3 45.3 4 13 1.3 14.8 
Nina Control 6 475.91 54.4 45.3 4 13 1.3 14.8 
Nina Control 7 482.27 54.5 45.3 4 14 1.4 15.2 
Nina Control 8 487.27 54.5 45.3 4 15 1.5 15.7 
Nina Control 9 488.64 54.5 45.3 4 15 1.5 15.7 
Nina Control 10 486.36 54.5 45.3 3 15 1.5 15.7 
Nina Control 11 488.64 54.5 45.3 3 15 1.5 15.7 
Nina Control 12 494.09 54.5 45.3 3 16 1.6 16.2 
Nina Control 13 491.82 54.5 45.3 3 15 1.5 15.7 
  
46
Appendix Table 14A (Continued). Physical data collected on project horses. 
Horse Group Week BW  Forearm Gaskin Rib Fat  Rump Fat Rump Fat Body Fat 
   (kg) (cm)  (cm) (mm)  (mm)  (cm) (%)  
Marla Control 0 485.00 54.6 49.1 5 6 0.6 11.5 
Marla Control 1 486.36 54.6 48.7 4 8 0.8 12.4 
Marla Control 2 477.27 54.6 48.8 4 8 0.8 12.4 
Marla Control 3 493.64 54.8 48.9 4 7 0.7 11.9 
Marla Control 4 495.45 54.9 49.1 4 8 0.8 12.4 
Marla Control 5 495.45 54.9 49.1 4 8 0.8 12.4 
Marla Control 6 488.64 54.9 49.1 4 7 0.7 11.9 
Marla Control 7 495.45 54.9 49.1 4 7 0.7 11.9 
Marla Control 8 495.45 55.0 49.0 4 8 0.8 12.4 
Marla Control 9 498.64 55.0 49.0 4 8 0.8 12.4 
Marla Control 10 490.91 55.0 49.0 3 8 0.8 12.4 
Marla Control 11 491.82 55.0 49.0 3 8 0.8 12.4 
Marla Control 12 489.55 55.0 49.0 3 8 0.8 12.4 
Marla Control 13 487.27 55.0 49.0 4 7 0.7 11.9 
          
Faces Control 0 415.45 53.9 45.1 4 3 0.3 10.1 
Faces Control 1 418.64 53.9 44.9 4 5 0.5 11.0 
Faces Control 2 406.82 53.9 45.0 3 4 0.4 10.5 
Faces Control 3 415.91 54.1 45.3 4 3 0.3 10.1 
Faces Control 4 421.82 54.1 45.3 5 4 0.4 10.5 
Faces Control 5 419.09 54.1 45.3 4 3 0.3 10.1 
Faces Control 6 422.73 54.2 45.3 4 3 0.3 10.1 
Faces Control 7 426.36 54.3 45.4 4 5 0.5 11.0 
Faces Control 8 427.27 54.4 45.4 4 5 0.5 11.0 
Faces Control 9 426.82 54.4 45.4 4 7 0.7 11.9 
Faces Control 10 425.91 54.5 45.4 3 6 0.6 11.5 
Faces Control 11 429.55 54.5 45.4 3 7 0.7 11.9 
Faces Control 12 435.45 54.5 45.4 3 8 0.8 12.4 
Faces Control 13 443.18 54.5 45.5 3 7 0.7 11.9 
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Appendix Table 14A (Continued). Physical data collected on project horses. 
Horse Group Week BW  Forearm Gaskin Rib Fat  Rump Fat Rump Fat Body Fat 
   (kg) (cm)  (cm) (mm)  (mm)  (cm) (%)  
Loreal Control 0 442.73 53.7 46.6 6 3 0.3 10.1 
Loreal Control 1 450.00 53.7 46.1 6 5 0.5 11.0 
Loreal Control 2 438.64 52.5 46.1 4 7 0.7 11.9 
Loreal Control 3 445.45 52.9 46.3 3 6 0.6 11.5 
Loreal Control 4 447.73 52.9 46.3 3 5 0.5 11.0 
Loreal Control 5 445.00 52.9 46.3 2 4 0.4 10.5 
Loreal Control 6 440.91 52.9 46.3 2 5 0.5 11.0 
Loreal Control 7 445.00 53.0 46.3 2 5 0.5 11.0 
Loreal Control 8 445.45 53.0 46.3 3 5 0.5 11.0 
Loreal Control 9 445.45 53.0 46.3 4 4 0.4 10.5 
Loreal Control 10 454.54 53.0 46.3 3 5 0.5 11.0 
Loreal Control 11 447.73 53.0 46.3 2 9 0.9 12.9 
Loreal Control 12 449.09 53.0 46.3 3 7 0.7 11.9 
Loreal Control 13 451.82 53.0 46.3 3 7 0.7 11.9 
          
Slimer Control 0 430.00 51.0 45.5 5 4 0.4 10.5 
Slimer Control 1 436.36 49.5 44.6 5 4 0.4 10.5 
Slimer Control 2 436.36 50.3 44.8 3 3 0.3 10.1 
Slimer Control 3 447.73 50.3 45.0 3 3 0.3 10.1 
Slimer Control 4 443.18 50.3 45.0 4 4 0.4 10.5 
Slimer Control 5 435.45 50.4 45.0 4 4 0.4 10.5 
Slimer Control 6 440.45 50.5 45.0 4 4 0.4 10.5 
Slimer Control 7 446.36 50.5 45.0 4 4 0.4 10.5 
Slimer Control 8 449.55 50.5 45.0 3 6 0.6 11.5 
Slimer Control 9 452.73 50.5 45.1 3 11 1.1 13.8 
Slimer Control 10 451.36 50.5 45.1 3 10 1 13.3 
Slimer Control 11 452.27 50.5 45.1 3 11 1.1 13.8 
Slimer Control 12 450.45 50.5 45.1 3 11 1.1 13.8 
Slimer Control 13 452.73 50.5 45.2 3 10 1 13.3 
  
48
Appendix Table 14A (Continued). Physical data collected on project horses. 
Horse Group Week BW  Forearm Gaskin Rib Fat  Rump Fat Rump Fat Body Fat 
   (kg) (cm)  (cm) (mm)  (mm)  (cm) (%)  
Lena Control 0 432.73 54.5 44.9 4 5 0.5 11.0 
Lena Control 1 442.27 54.3 44.8 2 6 0.6 11.5 
Lena Control 2 442.27 54.5 44.8 4 6 0.6 11.5 
Lena Control 3 447.73 54.5 44.8 3 7 0.7 11.9 
Lena Control 4 442.27 54.5 44.8 3 7 0.7 11.9 
Lena Control 5 440.45 54.5 44.8 3 8 0.8 12.4 
Lena Control 6 436.82 54.4 44.8 2 8 0.8 12.4 
Lena Control 7 445.45 54.6 44.8 2 9 0.9 12.9 
Lena Control 8 452.73 54.6 44.8 2 9 0.9 12.9 
Lena Control 9 454.54 54.6 44.8 2 9 0.9 12.9 
Lena Control 10 447.73 54.6 44.9 2 10 1 13.3 
Lena Control 11 450.45 54.6 45.0 2 10 1 13.3 
Lena Control 12 455.45 54.6 45.0 3 9 0.9 12.9 
Lena Control 13 453.64 54.6 45.0 3 10 1 13.3 
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Appendix Table 15A. Reproductive ultrasonographic measurements in project horses.
Horse Group Cycle Time to Ovulation Ovulatory Size 
       (d)  (mm) 
Dee RAC 1 45 44 
Dee RAC 2 21 34 
Dee RAC 3 28 37 
     
Freckles RAC 1 17 37 
Freckles RAC 2 21 40 
Freckles RAC 3 18 38 
Freckles RAC 4 21 33 
Freckles RAC 5 21 37 
     
Missy RAC 1 24 44 
Missy RAC 2 21 48 
Missy RAC 3 21 38 
     
Mary Kay RAC 1 18 39 
Mary Kay RAC 2 24 36 
Mary Kay RAC 3 18 43 
Mary Kay RAC 4 17 35 
Mary Kay RAC 5 21 41 
     
Blue RAC 1 67 35 
     
Scoot RAC 1 46 30 
Scoot RAC 2 21 39 
Scoot RAC 3 18 30 
     
Prissy RAC 1 17 30 
Prissy RAC 2 25 36 
Prissy RAC 3 28 28 
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Appendix Table 15A (Continued). Reproductive ultrasonographic measurements in 
project horses. 
Horse Group Cycle Time to Ovulation Ovulatory Size 
       (d)  (mm) 
Sun Control 1 31 33 
Sun Control 2 46 36 
     
Nina Control 1 17 35 
Nina Control 2 21 37 
Nina Control 3 21 33 
Nina Control 4 21 44 
     
Marla Control 1 42 40 
Marla Control 2 18 38 
Marla Control 3 24 35 
     
Faces Control 1 21 34 
Faces Control 2 31 30 
Faces Control 3 18 38 
     
Loreal Control 1 10 39 
Loreal Control 2 21 39 
Loreal Control 3 18 36 
Loreal Control 4 24 37 
Loreal Control 5 18 31 
     
Slimer Control 1 28 33 
Slimer Control 2 21 20 
Slimer Control 3 24 33 
Slimer Control 4 18 35 
     
Lena Control 1 21 35 
Lena Control 2 25 43 
Lena Control 3 21 35 
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Appendix Table 16A. Serum leptin concentrations from project horses. 
Horse Group Week Leptin  Leptin 
      (ng/ml) Norm.  
Dee RAC 0 1.0709 0.0000 
Dee RAC 1 0.9921 -0.0788 
Dee RAC 2 1.0507 -0.0202 
Dee RAC 3 1.1106 0.0397 
Dee RAC 4 2.3652 1.2943 
Dee RAC 5 1.5354 0.4645 
Dee RAC 6 1.8650 0.7941 
Dee RAC 7 1.4938 0.4229 
Dee RAC 8 1.3546 0.2837 
Dee RAC 9 1.4727 0.4018 
Dee RAC 10 1.6409 0.5700 
Dee RAC 11 2.9632 1.8923 
Dee RAC 12 3.0391 1.9682 
Dee RAC 13 1.4053 0.3344 
     
Missy RAC 0 1.6626 0.0000 
Missy RAC 1 1.8415 0.1789 
Missy RAC 2 2.0583 0.3957 
Missy RAC 3 1.7053 0.0427 
Missy RAC 4 1.7679 0.1053 
Missy RAC 5 1.5785 -0.0841 
Missy RAC 6 1.9275 0.2649 
Missy RAC 7 1.3984 -0.2642 
Missy RAC 8 1.5913 -0.0713 
Missy RAC 9 1.6041 -0.0585 
Missy RAC 10 1.9138 0.2512 
Missy RAC 11 1.7727 0.1101 
Missy RAC 12 1.9887 0.3261 
Missy RAC 13 2.6180 0.9554 
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Appendix Table 16A (Continued). Serum leptin concentrations from project horses. 
Horse Group Week Leptin  Leptin 
      (ng/ml) Norm.  
Mary Kay RAC 0 1.1724 0.0000 
Mary Kay RAC 1 1.3437 0.1713 
Mary Kay RAC 2 1.5754 0.4030 
Mary Kay RAC 3 1.5782 0.4058 
Mary Kay RAC 4 1.5732 0.4008 
Mary Kay RAC 5 2.0189 0.8465 
Mary Kay RAC 6 2.5116 1.3392 
Mary Kay RAC 7 1.2747 0.1023 
Mary Kay RAC 8 1.6259 0.4535 
Mary Kay RAC 9 2.8423 1.6699 
Mary Kay RAC 10 1.5944 0.4220 
Mary Kay RAC 11 1.5189 0.3465 
Mary Kay RAC 12 1.4649 0.2925 
Mary Kay RAC 13 1.4650 0.2926 
     
Blue RAC 0 1.4152 0.0000 
Blue RAC 1 1.6653 0.2501 
Blue RAC 2 1.7812 0.3660 
Blue RAC 3 1.3711 -0.0441 
Blue RAC 4 1.7315 0.3163 
Blue RAC 5 1.6740 0.2588 
Blue RAC 6 1.5064 0.0912 
Blue RAC 7 1.4794 0.0642 
Blue RAC 8 1.3684 -0.0468 
Blue RAC 9 1.5455 0.1303 
Blue RAC 10 1.4525 0.0373 
Blue RAC 11 1.4016 -0.0136 
Blue RAC 12 1.4414 0.0262 
Blue RAC 13 1.9265 0.5113 
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Appendix Table 16A (Continued). Serum leptin concentrations from project horses. 
Horse Group Week Leptin  Leptin 
      (ng/ml) Norm.  
Scoot RAC 0 1.9031 0.0000 
Scoot RAC 1 1.6935 -0.2096 
Scoot RAC 2 1.6686 -0.2345 
Scoot RAC 3 1.7425 -0.1606 
Scoot RAC 4 1.0062 -0.8969 
Scoot RAC 5 1.3751 -0.5280 
Scoot RAC 6 1.2248 -0.6783 
Scoot RAC 7 1.0589 -0.8442 
Scoot RAC 8 1.7670 -0.1361 
Scoot RAC 9 1.1917 -0.7114 
Scoot RAC 10 1.2044 -0.6987 
Scoot RAC 11 1.1367 -0.7664 
Scoot RAC 12 1.7414 -0.1617 
Scoot RAC 13 1.2380 -0.6651 
     
Prissy RAC 0 2.5462 0.0000 
Prissy RAC 1 4.0372 1.4910 
Prissy RAC 2 3.4017 0.8555 
Prissy RAC 3 2.9063 0.3601 
Prissy RAC 4 3.5298 0.9836 
Prissy RAC 5 3.0448 0.4986 
Prissy RAC 6 3.5778 1.0316 
Prissy RAC 7 3.8389 1.2927 
Prissy RAC 8 4.1362 1.5900 
Prissy RAC 9 3.9537 1.4075 
Prissy RAC 10 4.0822 1.5360 
Prissy RAC 11 4.2799 1.7337 
Prissy RAC 12 4.0943 1.5481 
Prissy RAC 13 3.6617 1.1155 
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Appendix Table 16A (Continued). Serum leptin concentrations from project horses. 
Horse Group Week Leptin  Leptin 
      (ng/ml) Norm.  
Sun Control 0 6.2769 0.0000 
Sun Control 1 7.3118 1.0349 
Sun Control 2 6.6174 0.3405 
Sun Control 3 6.6909 0.4140 
Sun Control 4 6.6227 0.3458 
Sun Control 5 7.2456 0.9687 
Sun Control 6 7.3698 1.0929 
Sun Control 7 7.0390 0.7621 
Sun Control 8 7.4070 1.1301 
Sun Control 9 7.5089 1.2320 
Sun Control 10 7.7734 1.4965 
Sun Control 11 8.2132 1.9363 
Sun Control 12 8.0114 1.7345 
Sun Control 13 7.6862 1.4093 
     
Nina Control 0 3.5952 0.0000 
Nina Control 1 3.8576 0.2624 
Nina Control 2 2.8610 -0.7342 
Nina Control 3 3.6594 0.0642 
Nina Control 4 3.5383 -0.0569 
Nina Control 5 3.3861 -0.2091 
Nina Control 6 3.6747 0.0795 
Nina Control 7 4.0120 0.4168 
Nina Control 8 4.3453 0.7501 
Nina Control 9 4.2011 0.6059 
Nina Control 10 4.3924 0.7972 
Nina Control 11 3.8701 0.2749 
Nina Control 12 4.4252 0.8300 
Nina Control 13 4.2584 0.6632 
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Appendix Table 16A (Continued). Serum leptin concentrations from project horses. 
Horse Group Week Leptin  Leptin 
      (ng/ml) Norm.  
Marla Control 0 2.8376 0.0000 
Marla Control 1 3.6587 0.8211 
Marla Control 2 3.1769 0.3393 
Marla Control 3 2.4040 -0.4336 
Marla Control 4 3.1502 0.3126 
Marla Control 5 3.0988 0.2612 
Marla Control 6 3.0924 0.2548 
Marla Control 7 3.6662 0.8286 
Marla Control 8 2.1348 -0.7028 
Marla Control 9 3.2288 0.3912 
Marla Control 10 2.1701 -0.6675 
Marla Control 11 2.4251 -0.4125 
Marla Control 12 1.9636 -0.8740 
Marla Control 13 1.8144 -1.0232 
     
Faces Control 0 1.5420 0.0000 
Faces Control 1 1.0542 -0.4878 
Faces Control 2 1.8646 0.3226 
Faces Control 3 1.2614 -0.2806 
Faces Control 4 1.7261 0.1841 
Faces Control 5 1.8479 0.3059 
Faces Control 6 1.5001 -0.0419 
Faces Control 7 1.2459 -0.2961 
Faces Control 8 1.0387 -0.5033 
Faces Control 9 1.0571 -0.4849 
Faces Control 10 1.7649 0.2229 
Faces Control 11 1.6167 0.0747 
Faces Control 12 1.5482 0.0062 
Faces Control 13 1.0369 -0.5051 
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Appendix Table 16A (Continued). Serum leptin concentrations from project horses. 
Horse Group Week Leptin  Leptin 
      (ng/ml) Norm.  
Loreal Control 0 1.5887 0.0000 
Loreal Control 1 1.0860 -0.5027 
Loreal Control 2 1.4758 -0.1129 
Loreal Control 3 1.5048 -0.0839 
Loreal Control 4 1.2146 -0.3741 
Loreal Control 5 1.4498 -0.1389 
Loreal Control 6 1.3194 -0.2693 
Loreal Control 7 1.1254 -0.4633 
Loreal Control 8 1.5935 0.0048 
Loreal Control 9 1.1587 -0.4300 
Loreal Control 10 0.9309 -0.6578 
Loreal Control 11 1.0393 -0.5494 
Loreal Control 12 1.0782 -0.5105 
Loreal Control 13 1.2059 -0.3828 
     
Slimer Control 0 1.3104 0.0000 
Slimer Control 1 3.9064 2.5960 
Slimer Control 2 1.7764 0.4660 
Slimer Control 3 1.7273 0.4169 
Slimer Control 4 1.8350 0.5246 
Slimer Control 5 1.8128 0.5024 
Slimer Control 6 2.0512 0.7408 
Slimer Control 7 1.9534 0.6430 
Slimer Control 8 2.6900 1.3796 
Slimer Control 9 2.2965 0.9861 
Slimer Control 10 2.2717 0.9613 
Slimer Control 11 2.0993 0.7889 
Slimer Control 12 2.3238 1.0134 
Slimer Control 13 1.4757 0.1653 
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Appendix Table 16A (Continued). Serum leptin concentrations from project horses. 
Horse Group Week Leptin  Leptin 
      (ng/ml) Norm.  
Lena Control 0 1.5564 0.0000 
Lena Control 1 1.5353 -0.0211 
Lena Control 2 1.5676 0.0112 
Lena Control 3 1.3092 -0.2472 
Lena Control 4 1.5996 0.0432 
Lena Control 5 1.5636 0.0072 
Lena Control 6 1.6883 0.1319 
Lena Control 7 1.8818 0.3254 
Lena Control 8 1.7476 0.1912 
Lena Control 9 1.9948 0.4384 
Lena Control 10 2.0381 0.4817 
Lena Control 11 1.8493 0.2929 
Lena Control 12 2.8869 1.3305 
Lena Control 13 2.5553 0.9989 
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Appendix Table 17A. Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Dee RAC 0 0.4  
Dee RAC 2 0.4  
Dee RAC 4 0.3  
Dee RAC 6 0.9  
Dee RAC 8 1.5  
Dee RAC 10 1.5  
Dee RAC 12 1.8  
Dee RAC 14 9.0  
Dee RAC 16 2.1  
Dee RAC 18 0.5  
Dee RAC 20 0.3  
Dee RAC 22 0.3  
Dee RAC 24 0.4  
Dee RAC 26 0.3  
Dee RAC 28 0.3  
Dee RAC 30 0.5  
Dee RAC 32 0.8  
Dee RAC 34 2.6  
Dee RAC 36 3.2  
Dee RAC 38 2.5  
Dee RAC 40 1.2  
Dee RAC 42 0.7  
Dee RAC 44 0.4  
Dee RAC 46 0.3  
Dee RAC 48 0.3  
Dee RAC 50 0.4  
Dee RAC 52 0.8  
Dee RAC 54 0.9  
Dee RAC 56 1.2  
Dee RAC 58 1.5  
Dee RAC 60 1.6  
Dee RAC 62 0.7  
Dee RAC 64 0.2  
Dee RAC 66 0.2  
Dee RAC 68 0.3  
Dee RAC 70 0.3  
Dee RAC 72 0.3  
Dee RAC 74 0.3  
Dee RAC 76 0.4  
Dee RAC 78 1.1  
Dee RAC 80 1.3  
Dee RAC 82 1.2  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Dee RAC 84 1.2  
Dee RAC 86 2.2  
Dee RAC 88 2.8  
Dee RAC 90 0.9  
     
Missy RAC 0 0.7  
Missy RAC 2 0.4  
Missy RAC 4 0.7  
Missy RAC 6 0.6  
Missy RAC 8 0.6  
Missy RAC 10 0.3  
Missy RAC 12 0.7  
Missy RAC 14 1.1  
Missy RAC 16 1.5  
Missy RAC 18 1.6  
Missy RAC 20 0.3  
Missy RAC 22 0.7  
Missy RAC 24 0.4  
Missy RAC 26 0.5  
Missy RAC 28 0.3  
Missy RAC 30 0.5  
Missy RAC 32 0.3  
Missy RAC 34 0.6  
Missy RAC 36 0.6  
Missy RAC 38 0.7  
Missy RAC 40 0.9  
Missy RAC 42 0.6  
Missy RAC 44 0.6  
Missy RAC 46 0.4  
Missy RAC 48 0.4  
Missy RAC 50 0.5  
Missy RAC 52 0.5  
Missy RAC 54 0.4  
Missy RAC 56 0.4  
Missy RAC 58 0.4  
Missy RAC 60 0.5  
Missy RAC 62 0.7  
Missy RAC 64 0.6  
Missy RAC 66 0.3  
Missy RAC 68 1.1  
Missy RAC 70 0.4  
Missy RAC 72 0.4  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Missy RAC 74 0.1  
Missy RAC 76 0.3  
Missy RAC 78 0.3  
Missy RAC 80 0.3  
Missy RAC 82 0.5  
Missy RAC 84 0.6  
Missy RAC 86 0.7  
Missy RAC 88 0.8  
Missy RAC 90 0.6  
     
Mary Kay RAC 0 0.4  
Mary Kay RAC 2 0.4  
Mary Kay RAC 4 0.6  
Mary Kay RAC 6 1.2  
Mary Kay RAC 8 0.6  
Mary Kay RAC 10 0.4  
Mary Kay RAC 12 0.2  
Mary Kay RAC 14 0.4  
Mary Kay RAC 16 0.4  
Mary Kay RAC 18 0.4  
Mary Kay RAC 20 0.3  
Mary Kay RAC 22 1.4  
Mary Kay RAC 24 1.4  
Mary Kay RAC 26 1.3  
Mary Kay RAC 28 0.8  
Mary Kay RAC 30 0.3  
Mary Kay RAC 32 0.4  
Mary Kay RAC 34 0.4  
Mary Kay RAC 36 0.2  
Mary Kay RAC 38 0.3  
Mary Kay RAC 40 0.2  
Mary Kay RAC 42 1.3  
Mary Kay RAC 44 0.8  
Mary Kay RAC 46 1.0  
Mary Kay RAC 48 1.1  
Mary Kay RAC 50 1.1  
Mary Kay RAC 52 0.5  
Mary Kay RAC 54 1.2  
Mary Kay RAC 56 0.2  
Mary Kay RAC 58 0.5  
Mary Kay RAC 60 0.3  
Mary Kay RAC 62 0.4  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Mary Kay RAC 64 1.6  
Mary Kay RAC 66 1.5  
Mary Kay RAC 68 0.5  
Mary Kay RAC 70 0.6  
Mary Kay RAC 72 3.2  
Mary Kay RAC 74 0.4  
Mary Kay RAC 76 0.3  
Mary Kay RAC 78 0.3  
Mary Kay RAC 80 0.6  
Mary Kay RAC 82 0.9  
Mary Kay RAC 84 3.1  
Mary Kay RAC 86 0.6  
Mary Kay RAC 88 1.7  
Mary Kay RAC 90 0.6  
     
Blue RAC 0 1.1  
Blue RAC 2 1.8  
Blue RAC 4 3.0  
Blue RAC 6 14.2  
Blue RAC 8 17.1  
Blue RAC 10 6.6  
Blue RAC 12 2.3  
Blue RAC 14 0.9  
Blue RAC 16 0.8  
Blue RAC 18 0.9  
Blue RAC 20 0.5  
Blue RAC 22 1.1  
Blue RAC 24 2.0  
Blue RAC 26 6.8  
Blue RAC 28 6.7  
Blue RAC 30 5.1  
Blue RAC 32 2.1  
Blue RAC 34 0.7  
Blue RAC 36 0.9  
Blue RAC 38 0.8  
Blue RAC 40 0.7  
Blue RAC 42 1.1  
Blue RAC 44 1.3  
Blue RAC 46 0.6  
Blue RAC 48 1.0  
Blue RAC 50 0.7  
Blue RAC 52 0.8  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Blue RAC 54 0.8  
Blue RAC 56 0.6  
Blue RAC 58 0.4  
Blue RAC 60 0.5  
Blue RAC 62 0.3  
Blue RAC 64 1.1  
Blue RAC 66 0.9  
Blue RAC 68 0.7  
Blue RAC 70 0.7  
Blue RAC 72 0.7  
Blue RAC 74 0.5  
Blue RAC 76 0.6  
Blue RAC 78 0.6  
Blue RAC 80 0.7  
Blue RAC 82 0.8  
Blue RAC 84 0.4  
Blue RAC 86 1.0  
Blue RAC 88 0.7  
Blue RAC 90 0.3  
     
Scoot RAC 0 2.0  
Scoot RAC 2 0.8  
Scoot RAC 4 0.5  
Scoot RAC 6 0.7  
Scoot RAC 8 0.9  
Scoot RAC 10 0.3  
Scoot RAC 12 0.3  
Scoot RAC 14 0.3  
Scoot RAC 16 0.2  
Scoot RAC 18 0.1  
Scoot RAC 20 0.3  
Scoot RAC 22 0.1  
Scoot RAC 24 0.1  
Scoot RAC 26 0.1  
Scoot RAC 28 0.4  
Scoot RAC 30 0.3  
Scoot RAC 32 0.2  
Scoot RAC 34 0.1  
Scoot RAC 36 0.1  
Scoot RAC 38 0.4  
Scoot RAC 40 0.1  
Scoot RAC 42 0.2  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Scoot RAC 44 0.2  
Scoot RAC 46 0.1  
Scoot RAC 48 0.2  
Scoot RAC 50 0.1  
Scoot RAC 52 0.4  
Scoot RAC 54 0.4  
Scoot RAC 56 0.1  
Scoot RAC 58 0.2  
Scoot RAC 60 0.3  
Scoot RAC 62 0.2  
Scoot RAC 64 0.8  
Scoot RAC 66 2.0  
Scoot RAC 68 0.2  
Scoot RAC 70 0.1  
Scoot RAC 72 0.1  
Scoot RAC 74 0.6  
Scoot RAC 76 0.1  
Scoot RAC 78 0.6  
Scoot RAC 80 0.5  
Scoot RAC 82 0.4  
Scoot RAC 84 0.1  
Scoot RAC 86 0.1  
Scoot RAC 88 0.1  
Scoot RAC 90 0.1  
     
Prissy RAC 0 0.7  
Prissy RAC 2 0.3  
Prissy RAC 4 0.4  
Prissy RAC 6 1.0  
Prissy RAC 8 2.1  
Prissy RAC 10 0.5  
Prissy RAC 12 0.6  
Prissy RAC 14 1.0  
Prissy RAC 16 0.9  
Prissy RAC 18 0.7  
Prissy RAC 20 0.4  
Prissy RAC 22 0.6  
Prissy RAC 24 0.6  
Prissy RAC 26 0.5  
Prissy RAC 28 0.5  
Prissy RAC 30 0.4  
Prissy RAC 32 0.3  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Prissy RAC 34 0.4  
Prissy RAC 36 0.4  
Prissy RAC 38 0.3  
Prissy RAC 40 0.2  
Prissy RAC 42 0.2  
Prissy RAC 44 0.3  
Prissy RAC 46 0.3  
Prissy RAC 48 0.2  
Prissy RAC 50 0.2  
Prissy RAC 52 0.2  
Prissy RAC 54 0.2  
Prissy RAC 56 0.2  
Prissy RAC 58 0.2  
Prissy RAC 60 0.2  
Prissy RAC 62 0.2  
Prissy RAC 64 0.2  
Prissy RAC 66 0.2  
Prissy RAC 68 0.2  
Prissy RAC 70 0.2  
Prissy RAC 72 0.2  
Prissy RAC 74 0.2  
Prissy RAC 76 0.1  
Prissy RAC 78 0.2  
Prissy RAC 80 0.2  
Prissy RAC 82 0.2  
Prissy RAC 84 0.3  
Prissy RAC 86 0.2  
Prissy RAC 88 0.2  
Prissy RAC 90 0.2  
     
Sun Control 0 0.8  
Sun Control 2 0.5  
Sun Control 4 1.4  
Sun Control 6 3.0  
Sun Control 8 3.5  
Sun Control 10 2.5  
Sun Control 12 2.4  
Sun Control 14 2.5  
Sun Control 16 3.2  
Sun Control 18 5.6  
Sun Control 20 2.3  
Sun Control 22 1.3  
  
65
Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Sun Control 24 1.3  
Sun Control 26 1.2  
Sun Control 28 0.7  
Sun Control 30 0.6  
Sun Control 32 0.4  
Sun Control 34 0.5  
Sun Control 36 0.4  
Sun Control 38 0.3  
Sun Control 40 0.3  
Sun Control 42 0.4  
Sun Control 44 0.4  
Sun Control 46 0.5  
Sun Control 48 0.2  
Sun Control 50 0.2  
Sun Control 52 0.4  
Sun Control 54 0.3  
Sun Control 56 0.3  
Sun Control 58 0.3  
Sun Control 60 0.3  
Sun Control 62 0.3  
Sun Control 64 0.4  
Sun Control 66 0.3  
Sun Control 68 0.3  
Sun Control 70 0.7  
Sun Control 72 0.3  
Sun Control 74 0.7  
Sun Control 76 0.5  
Sun Control 78 0.4  
Sun Control 80 0.5  
Sun Control 82 0.3  
Sun Control 84 0.2  
Sun Control 86 0.3  
Sun Control 88 0.2  
Sun Control 90 0.5  
     
Nina Control 0 0.9  
Nina Control 2 1.1  
Nina Control 4 1.0  
Nina Control 6 2.9  
Nina Control 8 3.7  
Nina Control 10 12.1  
Nina Control 12 5.8  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Nina Control 14 2.7  
Nina Control 16 1.4  
Nina Control 18 1.6  
Nina Control 20 1.2  
Nina Control 22 1.2  
Nina Control 24 1.4  
Nina Control 26 2.7  
Nina Control 28 3.3  
Nina Control 30 4.8  
Nina Control 32 2.5  
Nina Control 34 3.7  
Nina Control 36 2.0  
Nina Control 38 1.4  
Nina Control 40 1.3  
Nina Control 42 1.3  
Nina Control 44 1.2  
Nina Control 46 1.3  
Nina Control 48 2.2  
Nina Control 50 2.3  
Nina Control 52 5.3  
Nina Control 54 6.8  
Nina Control 56 8.4  
Nina Control 58 2.5  
Nina Control 60 1.3  
Nina Control 62 1.2  
Nina Control 64 0.8  
Nina Control 66 1.0  
Nina Control 68 1.4  
Nina Control 70 3.0  
Nina Control 72 4.0  
Nina Control 74 5.3  
Nina Control 76 4.8  
Nina Control 78 2.8  
Nina Control 80 3.0  
Nina Control 82 1.6  
Nina Control 84 1.5  
Nina Control 86 1.6  
Nina Control 88 1.8  
Nina Control 90 1.8  
     
Marla Control 0 2.2  
Marla Control 2 2.0  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Marla Control 4 1.1  
Marla Control 6 1.0  
Marla Control 8 1.5  
Marla Control 10 2.0  
Marla Control 12 1.1  
Marla Control 14 1.5  
Marla Control 16 1.3  
Marla Control 18 1.7  
Marla Control 20 1.7  
Marla Control 22 1.8  
Marla Control 24 2.0  
Marla Control 26 1.0  
Marla Control 28 1.0  
Marla Control 30 1.4  
Marla Control 32 1.3  
Marla Control 34 1.1  
Marla Control 36 1.5  
Marla Control 38 1.5  
Marla Control 40 1.7  
Marla Control 42 1.1  
Marla Control 44 1.1  
Marla Control 46 1.7  
Marla Control 48 2.0  
Marla Control 50 2.2  
Marla Control 52 7.2  
Marla Control 54 9.3  
Marla Control 56 3.9  
Marla Control 58 3.7  
Marla Control 60 2.4  
Marla Control 62 2.6  
Marla Control 64 1.3  
Marla Control 66 1.9  
Marla Control 68 2.4  
Marla Control 70 1.2  
Marla Control 72 1.4  
Marla Control 74 2.4  
Marla Control 76 3.4  
Marla Control 78 4.5  
Marla Control 80 6.3  
Marla Control 82 2.2  
Marla Control 84 1.9  
Marla Control 86 1.5  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Marla Control 88 1.4  
Marla Control 90 1.0  
     
Faces Control 0 1.8  
Faces Control 2 5.0  
Faces Control 4 3.4  
Faces Control 6 2.4  
Faces Control 8 2.3  
Faces Control 10 2.9  
Faces Control 12 1.5  
Faces Control 14 1.2  
Faces Control 16 1.6  
Faces Control 18 2.1  
Faces Control 20 2.3  
Faces Control 22 3.7  
Faces Control 24 2.0  
Faces Control 26 6.6  
Faces Control 28 7.0  
Faces Control 30 1.0  
Faces Control 32 2.2  
Faces Control 34 1.9  
Faces Control 36 1.7  
Faces Control 38 1.6  
Faces Control 40 1.1  
Faces Control 42 1.9  
Faces Control 44 3.4  
Faces Control 46 2.1  
Faces Control 48 2.7  
Faces Control 50 4.7  
Faces Control 52 9.5  
Faces Control 54 2.8  
Faces Control 56 3.2  
Faces Control 58 2.1  
Faces Control 60 1.7  
Faces Control 62 1.3  
Faces Control 64 1.6  
Faces Control 66 1.6  
Faces Control 68 1.0  
Faces Control 70 1.2  
Faces Control 72 1.3  
Faces Control 74 1.7  
Faces Control 76 2.5  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Faces Control 78 1.4  
Faces Control 80 1.0  
Faces Control 82 1.4  
Faces Control 84 0.9  
Faces Control 86 1.7  
Faces Control 88 0.6  
Faces Control 90 0.5  
     
Loreal Control 0 0.4  
Loreal Control 2 0.2  
Loreal Control 4 0.6  
Loreal Control 6 1.0  
Loreal Control 8 2.3  
Loreal Control 10 3.3  
Loreal Control 12 2.0  
Loreal Control 14 0.4  
Loreal Control 16 0.5  
Loreal Control 18 0.3  
Loreal Control 20 0.1  
Loreal Control 22 0.5  
Loreal Control 24 0.4  
Loreal Control 26 1.1  
Loreal Control 28 3.1  
Loreal Control 30 5.0  
Loreal Control 32 2.4  
Loreal Control 34 1.0  
Loreal Control 36 0.9  
Loreal Control 38 0.3  
Loreal Control 40 0.2  
Loreal Control 42 0.3  
Loreal Control 44 0.6  
Loreal Control 46 2.2  
Loreal Control 48 4.0  
Loreal Control 50 3.2  
Loreal Control 52 2.0  
Loreal Control 54 1.0  
Loreal Control 56 0.2  
Loreal Control 58 0.3  
Loreal Control 60 0.1  
Loreal Control 62 0.4  
Loreal Control 64 1.2  
Loreal Control 66 1.8  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Loreal Control 68 1.0  
Loreal Control 70 0.3  
Loreal Control 72 0.6  
Loreal Control 74 0.2  
Loreal Control 76 0.1  
Loreal Control 78 0.6  
Loreal Control 80 0.1  
Loreal Control 82 0.1  
Loreal Control 84 0.5  
Loreal Control 86 0.6  
Loreal Control 88 1.5  
Loreal Control 90 3.8  
     
Slimer Control 0 1.8  
Slimer Control 2 0.7  
Slimer Control 4 0.5  
Slimer Control 6 0.5  
Slimer Control 8 1.0  
Slimer Control 10 1.0  
Slimer Control 12 0.7  
Slimer Control 14 0.5  
Slimer Control 16 0.7  
Slimer Control 18 0.5  
Slimer Control 20 0.3  
Slimer Control 22 0.4  
Slimer Control 24 0.3  
Slimer Control 26 0.2  
Slimer Control 28 0.1  
Slimer Control 30 0.3  
Slimer Control 32 0.3  
Slimer Control 34 0.3  
Slimer Control 36 0.3  
Slimer Control 38 0.2  
Slimer Control 40 0.2  
Slimer Control 42 0.2  
Slimer Control 44 0.2  
Slimer Control 46 0.3  
Slimer Control 48 0.3  
Slimer Control 50 0.2  
Slimer Control 52 0.2  
Slimer Control 54 0.4  
Slimer Control 56 0.2  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Slimer Control 58 0.2  
Slimer Control 60 0.2  
Slimer Control 62 0.2  
Slimer Control 64 0.1  
Slimer Control 66 0.1  
Slimer Control 68 0.3  
Slimer Control 70 0.3  
Slimer Control 72 0.1  
Slimer Control 74 0.1  
Slimer Control 76 0.2  
Slimer Control 78 0.2  
Slimer Control 80 0.5  
Slimer Control 82 0.5  
Slimer Control 84 0.6  
Slimer Control 86 0.7  
Slimer Control 88 1.4  
Slimer Control 90 0.8  
     
Lena Control 0 0.9  
Lena Control 2 0.6  
Lena Control 4 0.8  
Lena Control 6 1.2  
Lena Control 8 2.0  
Lena Control 10 3.6  
Lena Control 12 2.2  
Lena Control 14 0.5  
Lena Control 16 0.6  
Lena Control 18 0.5  
Lena Control 20 0.5  
Lena Control 22 0.4  
Lena Control 24 0.2  
Lena Control 26 0.5  
Lena Control 28 1.2  
Lena Control 30 3.0  
Lena Control 32 3.9  
Lena Control 34 1.2  
Lena Control 36 0.4  
Lena Control 38 0.2  
Lena Control 40 0.3  
Lena Control 42 0.2  
Lena Control 44 0.3  
Lena Control 46 0.4  
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Appendix Table 17A (Continued). Serum LH concentrations from project horses. 
Horse Group Day LH  
   (ng/ml)  
Lena Control 48 0.5  
Lena Control 50 0.6  
Lena Control 52 0.8  
Lena Control 54 1.1  
Lena Control 56 1.6  
Lena Control 58 0.5  
Lena Control 60 0.2  
Lena Control 62 0.2  
Lena Control 64 0.2  
Lena Control 66 0.6  
Lena Control 68 0.1  
Lena Control 70 0.1  
Lena Control 72 0.2  
Lena Control 74 0.5  
Lena Control 76 0.4  
Lena Control 78 0.6  
Lena Control 80 0.9  
Lena Control 82 2.0  
Lena Control 84 0.7  
Lena Control 86 0.1  
Lena Control 88 0.3  
Lena Control 90 0.3  
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Appendix Table 18A. Mean LH concentrations by group for 
project horses. 
Group Day LH 
    (ng/ml) 
RAC 0 0.88 
RAC 2 0.68 
RAC 4 0.92 
RAC 6 3.10 
RAC 8 3.80 
RAC 10 1.60 
RAC 12 0.98 
RAC 14 2.12 
RAC 16 0.98 
RAC 18 0.70 
RAC 20 0.35 
RAC 22 0.70 
RAC 24 0.81 
RAC 26 1.58 
RAC 28 1.50 
RAC 30 1.18 
RAC 32 0.68 
RAC 34 0.80 
RAC 36 0.90 
RAC 38 0.83 
RAC 40 0.55 
RAC 42 0.68 
RAC 44 0.60 
RAC 46 0.45 
RAC 48 0.53 
RAC 50 0.50 
RAC 52 0.53 
RAC 54 0.65 
RAC 56 0.45 
RAC 58 0.53 
RAC 60 0.57 
RAC 62 0.42 
RAC 64 0.75 
RAC 66 0.85 
RAC 68 0.50 
RAC 70 0.38 
RAC 72 0.82 
RAC 74 0.35 
RAC 76 0.30 
RAC 78 0.52 
RAC 80 0.60 
RAC 82 0.67 
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Appendix Table 18A (Continued). Mean LH concentrations by 
group for project horses. 
Group Day LH 
    (ng/ml) 
RAC 84 0.95 
RAC 86 0.80 
RAC 88 1.05 
RAC 90 0.45 
   
Control 0 1.26 
Control 2 1.44 
Control 4 1.26 
Control 6 1.71 
Control 8 2.33 
Control 10 3.91 
Control 12 2.24 
Control 14 1.33 
Control 16 1.33 
Control 18 1.76 
Control 20 1.20 
Control 22 1.33 
Control 24 1.09 
Control 26 1.90 
Control 28 2.34 
Control 30 2.30 
Control 32 1.86 
Control 34 1.39 
Control 36 1.03 
Control 38 0.79 
Control 40 0.73 
Control 42 0.77 
Control 44 1.03 
Control 46 1.21 
Control 48 1.70 
Control 50 1.91 
Control 52 3.63 
Control 54 3.10 
Control 56 2.54 
Control 58 1.37 
Control 60 0.89 
Control 62 0.89 
Control 64 0.80 
Control 66 1.04 
Control 68 0.93 
Control 70 0.97 
Control 72 1.13 
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Appendix Table 18A (Continued). Mean LH concentrations by 
group for project horses. 
Group Day LH 
    (ng/ml) 
Control 76 1.70 
Control 78 1.50 
Control 80 1.76 
Control 82 1.16 
Control 84 0.90 
Control 86 0.93 
Control 88 1.03 
Control 90 1.24 
 
 
 
 
Appendix Table 19A. AUC values used to calculate total LH 
concentrations between groups 
Horse Group AUC 
      
Dee RAC 103.3 
Missy RAC 52.5 
Mary Kay RAC 71.7 
Blue RAC 186.6 
Scoot RAC 31.0 
Prissy RAC 35.5 
Sun Control 87.8 
Nina Control 254.7 
Marla Control 201.2 
Faces Control 216.8 
Loreal Control 111.1 
Slimer Control 37.0 
Lena Control 75.6 
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